国际口腔医学杂志

国际口腔医学杂志 ›› 2016, Vol. 43 ›› Issue (3): 366-370.doi: 10.7518/gjkq.2016.03.025

• 综述 • 上一篇    

沙利度胺在口腔黏膜病临床治疗实践中的安全性分析

宋韬,王冏珂,文静,陈谦明,曾昕   

  1. 口腔疾病研究国家重点实验室 华西口腔医院黏膜科（四川大学）成都 610041
  • 收稿日期:2015-08-22 修回日期:2015-12-11 出版日期:2016-05-01 发布日期:2016-05-01
  • 通讯作者: 曾昕，教授，博士，Email：zengxin22@163.com
  • 作者简介:宋韬，硕士，Email：sotall@163.com
  • 基金资助:
    国家自然科学基金（81472533）；国家卫生和计划生育委员会公益性行业专项基金（201502018）

Analysis of the safety of thalidomide in the treatment of oral mucosal diseases

Song Tao, Wang Jiongke, Wen Jing, Chen Qianming, Zeng Xin   

  1. State Key Laboratory of Oral Diseases, Dept. of Oral Medcine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China) This study was supported by Natural Science Foundation of China(81472533)and Nonprofit Industry Research Sepecific Fund of National Health and Family Planning Commission of China(201502018).
  • Received:2015-08-22 Revised:2015-12-11 Online:2016-05-01 Published:2016-05-01

RichHTML

4

PDF (PC)

626

被引次数

4

摘要： 沙利度胺诞生至今已经超过60年，目前广泛应用于炎症性疾病和自身免疫性疾病的治疗，包括多种口腔黏膜疾病的治疗。由于沙利度胺曾造成严重的致畸不良事件，所以较多医生对其在临床具体应用过程中的安全性尚存在一些疑问和顾虑。本文通过回顾分析有关沙利度胺的药物代谢动力学、药物作用机制以及临床治疗试验研究的文献，着重探讨沙利度胺的药物安全性、对育龄期患者的影响以及对儿童患者的影响等问题，以期为口腔黏膜病科医生提供更为全面的信息，确保其安全有效的应用。

关键词: 沙利度胺, 药物安全性, 口腔黏膜病, 育龄期妇女, 儿童, 沙利度胺, 药物安全性, 口腔黏膜病, 育龄期妇女, 儿童

Abstract: Thalidomide has been on the market for more than 60 years. It is currently used for the treatment of inflammatory and autoimmune diseases, including a variety of oral mucosal diseases. Due to its serious teratogenic effect, many oral medicine specialists are very cautious about the safety of thalidomide in the clinical application. To clarify its effect, especially on patients of childbearing age and children, we sum up the pharmacokinetics, mechanism and clinical studies of thalidomide. We hope that this review could provide oral medicine specialists with more comprehensive information on the clinical safety and effectiveness of thalidomide for the treatment of oral mucosal diseases.

Key words: thalidomide, drug safety, oral mucosal diseases, child-bearing period woman, pediatrics, thalidomide, drug safety, oral mucosal diseases, child-bearing period woman, pediatrics

中图分类号: 

  • R 781.5
[1] Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide[J]. Clin Pharmacokinet, 2004, 43(5):311-327.
[2] Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents[J]. Nat Rev Cancer, 2004, 4(4):314-322.
[3] Friderichs E. Studies on the CNS activity profile of thalidomide analogs(author’s transl)[J]. Arzneimittelforschung, 1982, 32(6):613-620.
[4] Youdim MB, Ashkenazi R. Serotonergic involvement in pharmacological action of the anxiolytic-sedatives thalidomide and supidimide[J]. Eur J Pharmacol, 1985, 119(1/2):39-46.
[5] Therapontos C, Erskine L, Gardner ER, et al. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation[J]. Proc Natl Acad Sci U S A, 2009, 106(21):8573-8578.
[6] Wines NY, Cooper AJ, Wines MP. Thalidomide in dermatology[J]. Australas J Dermatol, 2002, 43(4):229-240.
[7] Karim MY, Ruiz-Irastorza G, Khamashta MA, et al. Update on therapy—thalidomide in the treatment of lupus[J]. Lupus, 2001, 10(3):188-192.
[8] Lin AY, Brophy N, Fisher GA, et al. Phase Ⅱ study of thalidomide in patients with unresectable hepatocellular carcinoma[J]. Cancer, 2005, 103(1):119-125.
[9] Eriksson T, H?glund P, Turesson I, et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis[J]. J Pharm Pharmacol, 2003, 55(12):1701-1706.
[10] Shiah HS, Chao Y, Chen LT, et al. Phase Ⅰ and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2006, 58(5):654-664.
[11] Yang CS, Kim C, Antaya RJ. Review of thalidomide use in the pediatric population[J]. J Am Acad Dermatol, 2015, 72(4):703-711
[12] Franks ME, Macpherson GR, Figg WD. Thalidomide [J]. Lancet, 2004, 363(9423):1802-1811.
[13] Meganathan K, Jagtap S, Wagh V, et al. Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells[J]. PLoS One, 2012, 7(8):e44228.
[14] Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy[J]. Eur J Haematol, 2004, 72(6):403-409.
[15] Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients[J]. J Invest Dermatol, 2002, 119(5):1020-1026.
[16] Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study[J]. J Pediatr, 2004, 145(6):856-857.
[17] Nakamura K, Matsuzawa N, Ohmori S, et al. Clinical evidence of pharmacokinetic changes in thalidomide therapy[J]. Drug Metab Pharmacokinet, 2013, 28(1):38-43.
[18] Vianna FS, Lopez-Camelo JS, Leite JC, et al. Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil[J]. PLoS One, 2011, 6(7):e21735.
[19] Schuler-Faccini L, Soares RC, de Sousa AC, et al. New cases of thalidomide embryopathy in Brazil[J]. Birth Defects Res A Clin Mol Teratol, 2007, 79(9):671-672.
[20] Cheng S, Murphy R. Refractory aphthous ulceration treated with thalidomide: a report of 10 years’ clinical experience[J]. Clin Exp Dermatol, 2012, 37(2):132-135.
[21] Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group[J]. N Engl J Med, 1997, 336(21):1487-1493.
[22] Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus[J]. Int J Dermatol, 2000, 39(3):218-222.
[23] Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis[J]. Arch Dermatol, 1990, 126(7):923-927.
[24] Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial[J]. JAMA, 2013, 310(20):2164-2173.
[25] Samsoen M, Grosshans E, Basset A. Thalidomide in the treatment of discoid lupus erythematosus (D.L.E.)(author’s transl)[J]. Ann Dermatol Venereol, 1980, 107(6):515-523.
[26] Yasui K, Kobayashi N, Yamazaki T, et al. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation[J]. Curr Pharm Des, 2005, 11(3):395-401.
[27] Rigante D, La Torre F, Calcagno G, et al. Clinical response to thalidomide and colchicine in two siblings with Behcet’s disease carrying a single mutated MEFV allele[J]. Rheumatol Int, 2012, 32(6):1859-1860.
[28] Hello M, Barbarot S, Bastuji-Garin S, et al. Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis[J]. Medicine: Baltimore, 2010, 89(3):176-182.
（本文采编 王晴）
[1] 邓晓宇,仁青色格,霍媛媛,崔晨,亓文婷,韩轩,黄睿洁,周媛,朱林,邹静,旦增念扎. 西藏自治区城区和牧区儿童患龋情况与相关因素分析[J]. 国际口腔医学杂志, 2020, 47(4): 383-390.
[2] 于林彤,宋光泰. 铒激光在儿童口腔医学中的应用[J]. 国际口腔医学杂志, 2020, 47(3): 351-355.
[3] 崔钰嘉,孙建勋,周学东. 黄连素的生物学功能及治疗口腔疾病研究的进展[J]. 国际口腔医学杂志, 2020, 47(1): 115-120.
[4] 王晓波,林世耀,李霞. 母亲与儿童龋病关系的研究进展[J]. 国际口腔医学杂志, 2019, 46(4): 469-474.
[5] 赵金,赖光云,汪俊. 全身麻醉下儿童口腔疾病治疗家长接受度现况的研究进展[J]. 国际口腔医学杂志, 2018, 45(6): 739-744.
[6] 丁杰, 宋光泰. 微创技术在儿童龋病治疗中的应用[J]. 国际口腔医学杂志, 2018, 45(4): 473-479.
[7] 游文喆, 夏斌. 精神/智力残疾儿童的口腔健康促进和维护[J]. 国际口腔医学杂志, 2018, 45(4): 492-496.
[8] 刘晓华, 王恩博. 儿童埋伏多生牙拔除术锥形束计算机断层扫描影像学定位的应用进展[J]. 国际口腔医学杂志, 2018, 45(3): 295-300.
[9] 蔡东霖, 卢锐. 儿童复发性阿弗他溃疡病因学的研究进展[J]. 国际口腔医学杂志, 2018, 45(2): 145-149.
[10] 高雪彬, 张琦, 李晶, 毕也, 杨华, 黄洋. 低龄儿童行窝沟封闭术时酸蚀剂选择的临床研究[J]. 国际口腔医学杂志, 2017, 44(4): 433-436.
[11] 林赳, 余钒源, 方欣怡, 哈品, 龚彩霞, 石冰. 儿童口腔健康相关生存质量量表信度与效度的验证研究[J]. 国际口腔医学杂志, 2017, 44(4): 445-451.
[12] 孙丞君, 许方清, 陈阳平, 刘丰艺, 罗佳英, 夏彬彬. 错牙合畸形对城市和农村儿童日常生活质量影响的研究[J]. 国际口腔医学杂志, 2017, 44(3): 304-309.
[13] 黄振贤, 王巧静. 上颌快速扩弓治疗儿童阻塞性睡眠呼吸暂停综合征的研究进展[J]. 国际口腔医学杂志, 2017, 44(2): 218-221.
[14] 郑黎薇, 邹静, 夏斌, 刘英群, 黄洋, 赵今. 儿童乳磨牙金属预成冠的修复治疗[J]. 国际口腔医学杂志, 2017, 44(2): 125-129.
[15] 朱晸,史俊. 儿童下颌骨髁突骨折的治疗进展[J]. 国际口腔医学杂志, 2017, 44(2): 222-227.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张京剧. 青年期至中年期颅面复合体变化的头影测量研究[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 刘玲. 镍铬合金中铍对可铸造性和陶瓷金属结合力的影响[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 王昆润. 在种植体上制作固定义齿以后下颌骨密度的动态变化[J]. 国际口腔医学杂志, 1999, 26(06): .
[4] 王昆润. 重型颌面部炎症死亡和康复病例的实验室检查指标比较[J]. 国际口腔医学杂志, 1999, 26(06): .
[5] 逄键梁. 两例外胚层发育不良儿童骨内植入种植体后牙槽骨生长情况[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 温秀杰. 氟化物对牙本质脱矿抑制作用的体外实验研究[J]. 国际口腔医学杂志, 1999, 26(05): .
[7] 杨春惠. 耳颞神经在颞颌关节周围的分布[J]. 国际口腔医学杂志, 1999, 26(04): .
[8] 王昆润. 牙周炎加重期应选用何种抗生素[J]. 国际口腔医学杂志, 1999, 26(04): .
[9] 杨儒壮 孙宏晨 欧阳喈. 纳米级高分子支架材料在组织工程中的研究进展[J]. 国际口腔医学杂志, 2004, 31(02): 126 -128 .
[10] 严超然,李龙江. 肿瘤靶向药物载体系统的研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .